AR and nonpapillary renal cell carcinoma: However, combined administration of pazopanib and enzalutamide significantly suppressed ccRCC tumor growth, suggesting targeting AR with its inhibitor enzalutamide could enhance pazopanib efficacy (Fig. 7A, B).